Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- New Options Available in Cancer Pain Treatment: Janssen, Kyowa Hakko Seminar
December 15, 2003
- Wakamoto: Cost-cutting Boosts Profits
December 15, 2003
- BUSINESS NEWS IN BRIEF
December 15, 2003
- 2nd Edition of Int'l Headache Classification Previewed: Pfizer Seminar
December 15, 2003
- Basic Policy for Next NHI Pricing System Reform Presented
December 15, 2003
- NEW PRODUCTS
December 15, 2003
- DIAGNOSTIC NEWS IN BRIEF
December 15, 2003
- Price Discrepancy Rate Marks 6.3%: Price Survey
December 15, 2003
- Videophone-based Drug Sales to Be Approved
December 15, 2003
- MEDICAL DEVICE NEWS IN BRIEF
December 15, 2003
- Drug Price Revision Rate Next April to Be Lower than Previous 6.3%
December 15, 2003
- IMSJ, ACNielsen to Cooperate in OTC Drug Market Surveys
December 15, 2003
- WORLD NEWS IN BRIEF
December 15, 2003
- REGULATORY NEWS IN BRIEF
December 15, 2003
- Taisho, HP Japan Create First PMS Support System for OTC Drugs
December 15, 2003
- Approval of 3 New Drugs Incl. Olmes Recommended
December 15, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 15, 2003
- Semi-annual Business Results
December 15, 2003
- Semi-annual Business Results
December 15, 2003
- Kraft: Double-digit Growth in Sales, Profits
December 15, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…